This study highlights Luteolin's potential as a dual inhibitor of PDGFRα T674I and c-Kit D816H, mutations associated with drugresistance in gastrointestinal stromal tumors (GISTs). The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.